ORIC Pharma

$4.63 0.00% ($0.00)

Get ready to invest

About ORIC Pharma

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.

Popular Stocks	Price	Change
Bed Bath & Beyond BBBY	$20.65 29.06%	29.06%
AMTD International ADR AMTD	$2.81 24.34%	24.34%
Nu Holdings NU	$5.52 17.95%	17.95%
AMC AMC	$24.81 2.48%	2.48%
AMD AMD	$100.2 0.8%	0.8%
SoFi SOFI	$7.58 0.52%	0.52%
Ginkgo Bioworks Holdings DNA	$3.74 7.16%	7.16%
Snap SNAP	$12.61 3.02%	3.02%
Carnival CCL	$11.19 4.48%	4.48%
fuboTV FUBO	$6.35 44.98%	44.98%